Autoimmune Diseases  >>  Ilaris (canakinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ilaris (canakinumab) / Novartis
NCT00424346 / 2006-001550-27: Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Completed
2
274
US, Canada, Europe
Canakinumab, ACZ885, Placebo
Novartis
Rheumatoid Arthritis
09/08
10/09
NCT00504595 / 2006-004669-32: Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Completed
2
80
Europe, RoW
ACZ885 (investigational), Canakinumab, Placebo
Novartis
Rheumatoid Arthritis
09/08
09/08
NCT00487825 / 2006-001553-10: Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Completed
2
78
US, Europe
Canakinumab (investigational), ACZ885, Placebo, Methotrexate (MTX)
Novartis
Rheumatoid Arthritis
12/08
12/08
NCT01322321 / 2010-020166-20: ACZ885 in Type 1 Diabetes Mellitus

Withdrawn
2
0
US, Canada, Europe
ACZ885, Placebo
Novartis Pharmaceuticals
Diabetes Mellitus, Diabetes Type 1
06/11
 
NCT00505089 / 2006-004666-14: Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Terminated
1/2
11
Europe
ACZ885
Novartis
Rheumatoid Arthritis
05/09
 
NCT00426218 / 2006-001834-42: Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed
1/2
26
Europe
ACZ885
Novartis
Arthritis, Juvenile Rheumatoid
03/10
 

Download Options